Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. - Colson AE; Mills AM; Ramgopal MN; Bettacchi C; Osiyemi OO; Hinestrosa F; Crofoot G; Katner HP; Gatanaga H; Johnson M; Diamond TL; Barninger E; et al. (Lancet (London, England), 2026)